Susquehanna Downgrades Coley Pharmaceutical Group (COLY) to Neutral
More News related to COLY
- Susquehanna Downgrades Coley Pharmaceutical Group (COLY) to Neutral
- StreetInsider.com Unusual 11 Mid-Day Movers 11/16
- StreetInsider.com Notable Mergers and Acquisitions of the Day
- Pre-Open Movers 11/16: Garmin (GRMN) Surges After Dropping Bid, FedEx (FDX) Cuts Guidance
- IDP, ANDS, DVAX Could See Action Related to Pfizer's Deal to Acquire Coley
More News related to Downgrades
- UBS Downgrades Crucell N.V. (CRXL) to Neutral
- J.P. Morgan Upgrades Entergy (ETR); Downgrades Wisconsin Energy (WEC) - Cuts Price Targets
- J.P. Morgan Upgrades Peabody Energy (BTU); Downgrades Massey (MEE)
- Exane BNP Paribas Downgrades ARM Holdings (ARMH) to Neutral
- Thomas Weisel Downgrades Vital Images (VTAL) to Marketweight
Susquehanna downgrades Coley Pharmaceutical Group (Nasdaq: COLY) from Positive to Neutral.
Coley Pharmaceutical Group, Inc. is a biopharmaceutical company focused on discovering and developing a class of drug candidates for cancers, infectious diseases and respiratory disorders.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
